Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
Stelara may lose effect due to anti-drug antibodies, low drug levels, shifts in disease pathways, suboptimal dosing, or a new overlapping condition, even if it worked well at first. There are several factors to consider that could change your next steps; see below to understand more.
Doctors typically confirm active inflammation and diagnosis, check ustekinumab levels and antibodies, optimize dose or timing, and if needed switch to an IL-23 specific agent or another class such as anti-TNF, JAK, S1P, or integrin therapy, with urgent red flags like severe pain, high fever, or blood in stool requiring immediate care.
If you're asking yourself, "Why did Stelara stop working for me?" you're not alone. Many people with Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, or other inflammatory conditions experience strong improvement at first—only to notice symptoms slowly returning.
This can feel frustrating and confusing. The good news? There are medical reasons this happens, and there are clear next steps your doctor can take. Let's break it down in plain language.
Stelara (ustekinumab) is a biologic medication. It works by targeting specific immune system proteins—interleukin‑12 (IL‑12) and interleukin‑23 (IL‑23)—that drive inflammation.
By blocking these signals, Stelara helps:
For many people, it works very well. But biologics don't work the same way for everyone, and sometimes their effect changes over time.
There are two main scenarios doctors consider:
If you're asking, "Why did Stelara stop working for me after it helped before?", you're likely experiencing secondary loss of response.
Here are the most common reasons.
Although Stelara has a relatively low rate of antibody formation compared to some other biologics, it can still happen.
Your immune system may:
When this happens, drug levels drop and inflammation returns.
Doctors can check this with therapeutic drug monitoring, a blood test that measures:
If levels are low, dose adjustments may help.
Inflammatory diseases are complex. Over time:
In simple terms, the disease biology can shift. When that happens, blocking IL‑12/23 may no longer be enough.
This doesn't mean you did anything wrong. It means your immune system evolved.
Body weight, metabolism, and disease severity can influence how well Stelara works.
Some people may need:
Clinical guidelines support dose escalation in patients who lose response, especially in inflammatory bowel disease.
If you're wondering, "Why did Stelara stop working for me when nothing else changed?"—sometimes the answer is simply drug levels that are now too low.
Symptoms returning doesn't always mean Stelara failed.
Other possibilities include:
In rare cases, new neurological symptoms like numbness, vision changes, or weakness may signal an unrelated autoimmune condition. If you're experiencing these types of symptoms, you can use a free Multiple Sclerosis (MS) symptom checker to help identify patterns and determine whether you should discuss them with your doctor.
However, any new or worsening neurological symptoms should be discussed with a doctor promptly.
Sometimes symptoms improve, but underlying inflammation continues quietly.
Over time, this "smoldering" inflammation can:
This is why doctors often monitor:
Symptoms alone don't always tell the full story.
If you're thinking, "Why did Stelara stop working for me—and what now?", here's what typically happens next.
Your doctor may confirm:
Therapeutic drug monitoring can determine:
This information guides the next move.
Options may include:
Many patients regain response with dose optimization.
Newer IL‑23–specific medications are available. Some patients who lose response to Stelara respond to these.
Your doctor may recommend switching to:
If IL‑12/23 blockade is no longer effective, your doctor might consider:
Choice depends on:
While loss of response is common, some symptoms require urgent care:
If anything feels life-threatening or significantly worse than usual, seek emergency care and speak to a doctor immediately.
When Stelara stops working, people often feel:
This reaction is completely understandable.
The important thing to remember is this:
Loss of response is common in chronic inflammatory diseases. It does not mean you are out of options.
Medical treatments continue to evolve. New biologics and targeted therapies have expanded significantly in the last decade.
If you're still wondering, "Why did Stelara stop working for me?", consider bringing these questions to your next appointment:
Clear communication helps guide the next step.
If Stelara stopped working, the most likely reasons include:
The key takeaway: There are structured, evidence-based next steps.
You are not at the end of the road.
Work closely with your healthcare provider to:
And most importantly, speak to a doctor about any serious or life‑threatening symptoms immediately.
Modern medicine offers multiple pathways for controlling immune-driven disease. If one path stops working, another often can.
(References)
* Argüelles-Arias F, Cañas-Ojeda E, Benítez-Morales C, Castro-López M, Expósito-Suárez M, Loperena-Aguirrezabal A. Mechanisms of primary and secondary loss of response to ustekinumab in patients with Crohn's disease: a systematic review. Gastroenterol Rep (Oxf). 2021 Jul 20;9(4):287-295. doi: 10.1093/gasrep/goab026. PMID: 34295484; PMCID: PMC8294474.
* Zisblatt L, Abarbanel DN, Afzali A, Shah S, Lichtenstein GR. Immunogenicity of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Crohns Colitis. 2022 Mar 22;16(3):408-417. doi: 10.1093/ecco-jcc/jjab187. PMID: 35312019.
* Plevy R, Ungaro RC. Management of Primary and Secondary Nonresponse to Ustekinumab in Inflammatory Bowel Disease: A Review. Dig Dis Sci. 2023 Feb;68(2):413-424. doi: 10.1007/s10620-022-07380-6. Epub 2022 Mar 1. PMID: 35226299; PMCID: PMC9903126.
* Bitton A, Viazis N, Shah S, Lichtenstein GR. Therapeutic Drug Monitoring of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2021 Apr 1;55(4):279-287. doi: 10.1097/MCG.0000000000001391. PMID: 32483981.
* Moussavian M, Anamika K, Siffle L, Mankan H, Rubin DT. Treatment Strategies for Moderate-to-Severe Crohn's Disease After Ustekinumab Failure. J Clin Gastroenterol. 2023 Jul 1;57(6):601-608. doi: 10.1097/MCG.0000000000001799. Epub 2023 Jan 26. PMID: 36696412.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.